A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts

Oncology

Volumn 61, Issue 3, 2001, Pages 234-242

  Supino, Rosanna ^a   Polizzi, Donatella ^a   Pavesi, Raffaella ^a   Pratesi, Graziella ^a   Guano, Fulvio ^a   Capranico, Giovanni ^a   Palumbo, Manlio ^b   Sissi, Claudia ^b   Richter, Silvia ^b   Beggiolin, Gino ^c   Menta, Ernesto ^c   Pezzoni, Gabriella ^c   Spinelli, Silvano ^c   Torriani, Dante ^c   Carenini, Nives ^a   Dal Bo, Laura ^a   Facchinetti, Federica ^a   Tortoreto, Monica ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Novuspharma SpA   (Italy)

Author keywords

Anthrapyrazoles; Preclinical efficacy; Prostate carcinoma

Indexed keywords

2 [2 [(2 HYDROXYETHYL)AMINO]ETHYL] 5 [[2 (METHYLAMINO)ETHYL]AMINO]INDAZOLO[4,3 GH]ISOQUINOLIN 6(2H) ONE; 9 AZA ANTHRAPYRAZOLE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FREE RADICAL; LOSOXANTRONE; PROTEIN BCL 2; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CELL DESTRUCTION; CANCER MODEL; CANCER REGRESSION; CONTROLLED STUDY; DNA BINDING; DNA CLEAVAGE; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG EFFICACY; ENZYME ISOLATION; GENOTOXICITY; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTHRAQUINONES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOXORUBICIN; ETHANOLAMINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; INTERCALATING AGENTS; MALE; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; PYRAZOLONES; REMISSION INDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 18444417110     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055380     Document Type: Article

References (22)

1. New drugs. The anthrapyrazoles
2. 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation
3. Anthrapyrazole CI941: A highly active new agent in the treatment of advanced breast cancer
4. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4,3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles)
5. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts
6. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
7. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts
8. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay
9. Topoisomerase poisoning activity of novel disaccharide anthracyclines
10. DNA as a target in cancer chemotherapy. Measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens
11. Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells
12. Formaldehyde as a probe of DNA structure. I. Reaction with exocyclic amino groups of DNA bases
13. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells
14. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
15. Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells
16. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage
17. Aza-bioisosteres of 9,10-anthracenedione: A modulation of DNA sequence specificity
18. A phase II trial of Cl-958 in patients with hormone-refractory prostate cancer
19. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer
20. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones
21. Expression of delayed toxicity and lethal mutations in the progeny of human cells surviving exposure to radiation and other environmental mutagens
22. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure